- Companies
- Biolinq
Biolinq Funding, Investors & Competitors
Biolinq has raised $273M across 5 funding rounds, most recently a $100M Series C in March 2025.
Last Biolinq funding round
$100M
Series C · Mar 2025
Cumulative funding Biolinq raised
$273M
across 5 funding rounds
Key investors in Biolinq
M Ventures
RiverVest
LifeSci Venture Partners
Aphelion Capital
Hikma Ventures
Alpha Wave Ventures
Taisho Pharmaceutical Holdings
Features Capital
About Biolinq
Biolinq is a San Diego-based digital health company developing minimally invasive biosensors for continuous biomarker monitoring. Their electrochemical skin patches analyze interstitial fluid for glucose, lactate, and electrolytes, targeting diabetes management and athletic performance. Backed by J&J and others, the platform integrates with apps for real-time health data.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Product sales
Biolinq Funding History
Biolinq has raised a total of $273M across 5 funding rounds.
Biolinq's first fundraising round was a $10M Series A in November 2017. The most recent completed round was a $100M Series C in March 2025.
Biolinq funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2025 | Series C | Alpha Wave Ventures (lead); M Ventures; AXA Alternative Investments; Features Capital; LifeSci Venture Partners; Hikma Ventures; Taisho Pharmaceutical Holdings; RiverVest; Aphelion Capital | $100M | Biolinq Incorporated, a San Diego-based healthcare technology company, develops precision multi-analyte biosensors, focusing on intradermal wearable devices for continuous glucose monitoring to improve metabolic health, particularly for type 2 diabetes patients not on insulin. The company's initial product is an autonomous biosensor powered by tiny electrochemical sensors beneath the skin's surface, incorporating activity and sleep data, and featuring an integrated display that works with or without a phone. Biolinq has completed its US pivotal trial and submitted its investigational device to the FDA for regulatory review, advancing toward commercial readiness. On April 22, 2025, Biolinq closed a $100 million Series C funding round led by Alpha Wave Ventures, with participation from existing investors including RiverVest Venture Partners, AXA IM Alts (AXA Alternative Investments), LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital. The financing supports progression through the US regulatory approval process and preparation for market launch of the first intradermal glucose sensor. CEO Rich Yang emphasized bolstering commercial efforts, while Chair Dan Bradbury highlighted unlocking a new era of biosensing for accessible glucose information. Alpha Wave Global Chair Rick Gerson noted Biolinq's assembly of experts in biosensor technology, consumer electronics, and semiconductor manufacturing to redefine biowearables. This Series C follows a $58 million financing (bridge or Series B) approximately a year prior, led by Alpha Wave Ventures with similar investors including RiverVest, AXA IM Alts, Aphelion Capital, Features Capital, and Taisho, which supported pivotal trial completion and FDA submission. Earlier rounds included $4.75 million extended Series A in 2019 and $20 million Series A in 2017. |
| Apr 2024 | Undisclosed stage | Alpha Wave Ventures (lead); Features Capital; Taisho Pharmaceutical Holdings; Niterra Ventures; RiverVest; AXA Investment Managers; Senvest Capital; Pegasus Tech Ventures; Global Health Investment Corporation; Aphelion Capital | $58M | Biolinq Incorporated is a San Diego-based healthcare technology company developing precision multi-analyte wearable biosensors, primarily an intradermal glucose sensor for continuous monitoring beneath the skin's surface, targeting metabolic health especially for Type 2 diabetes patients not on insulin. The sensor integrates activity and sleep data into a single autonomous, needle-free wearable device with an integrated display, aiming to redefine biowearables by combining biosensor tech, consumer electronics, and semiconductor manufacturing. In April 2024, Biolinq completed a $58 million bridge financing round led by Alpha Wave Ventures, with participation from Niterra Ventures (jointly with Pegasus Tech Ventures), and existing investors including RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital, and Taisho Pharmaceutical. J.P. Morgan served as placement agent. The funds supported completion of the U.S. pivotal trial and FDA submission for the glucose sensor. The company had previously raised earlier rounds, positioning it to compete in the growing glucose-monitoring market. A subsequent $100 million Series C round was announced around April 2025, again led by Alpha Wave Ventures with participation from RiverVest, AXA IM Alts, Aphelion Capital, Taisho Pharmaceutical, Features Capital, and others including LifeSci Venture Partners, M Ventures, and Hikma Ventures. This later financing advanced commercial readiness post-pivotal trial and FDA submission. |
| Nov 2021 | Series B | RiverVest (lead) | $100M | Biolinq Incorporated is a San Diego-based healthcare technology company pioneering precision multi-analyte biosensors designed to improve metabolic health. The company's core platform features intradermal biosensors with tiny electrochemical sensors that measure glucose levels continuously just beneath the skin's surface, with initial focus on Type 2 diabetes patients not on insulin. In November 2021, Biolinq closed a $100 million Series B financing round led by RiverVest Venture Partners, supporting the company's transition from development stage toward commercial readiness. The funding was intended to support FDA submission and completion of a pivotal clinical trial for the company's autonomous intradermal glucose sensor. Co-founders Jared Tangney and Joshua Windmiller led the company's mission to make continuous sensing simple and more accessible, having spent over a decade developing the biosensor platform designed to provide context around metabolic health with integrated activity and sleep information. |
| Mar 2019 | Series A | Aphelion Capital (lead); JDRF T1D Fund (lead); LifeSci Venture Partners (lead); M Ventures; Hikma Ventures | $5M | Biolinq is a San Diego-based health technology company developing a minimally invasive, wirelessly-enabled electrochemical biosensor patch for continuous glucose monitoring and other biomarkers to simplify diabetes management. The company expanded its oversubscribed Series A financing in March 2019 with an additional $4.75 million to $4.8 million led by JDRF T1D Fund, Aphelion Capital, and LifeSci Venture Partners, joined by existing investors M Ventures and Hikma Ventures, bringing the total Series A to $15 million after an initial $10 million in late 2017. Funds supported advancement of the technology platform, additional clinical studies, and progress toward commercial feasibility following successful first clinical results in 2018. |
| Nov 2017 | Series A | M Ventures (lead); Grey Sky Venture Partners; LifeSci Venture Partners; Hikma Ventures; Three Leaf Ventures | $10M | Biolinq is a digital health company developing a wirelessly-enabled biosensor patch for continuous monitoring of multiple biomarkers, with its first product targeting painless blood glucose monitoring for diabetes patients. On November 27, 2017, Biolinq closed a $10M Series A financing round led by M Ventures, with participation from Hikma Ventures, Grey Sky Venture Partners, Three Leaf Ventures, LifeSci Venture Partners, and high-net-worth individuals specialized in diabetes. The funding aims to advance the minimally-invasive electrochemical biosensor platform technology toward clinical trials and commercialization, emphasizing low-cost manufacturing, factory calibration, and ease-of-use to improve access to continuous glucose monitoring. Edward Kliphuis from M Ventures and Lana Ghanem from Hikma Ventures joined the board. |
Who has invested in Biolinq?
17 investors have backed Biolinq across its funding rounds, including M Ventures, RiverVest, LifeSci Venture Partners, Aphelion Capital, Hikma Ventures and Alpha Wave Ventures.
Lead investors include Alpha Wave Ventures, RiverVest, Aphelion Capital, JDRF T1D Fund, LifeSci Venture Partners and 1 other investor.
Biolinq Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Nov 2017 | ||
| 3 | Lead | Nov 2017 | ||
| 3 | Participant | Nov 2017 | ||
| 3 | Lead | Nov 2021 | ||
| 3 | Lead | Mar 2019 | ||
| 2 | Participant | Apr 2024 | ||
| 2 | Lead | Apr 2024 | ||
| 2 | Participant | Apr 2024 | ||
| 1 | Lead | Mar 2019 | ||
| 1 | Participant | Mar 2025 | ||
| 1 | Participant | Nov 2017 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Apr 2024 | ||
This data is available for Pro users. Sign up to see all 17 Biolinq investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBiolinq Competitors
Biolinq competitors include listed companies like Johnson & Johnson, Thermo Fisher Scientific, Danaher and Agilent, and private ones like MindMaze and Galvanize Therapeutics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $8M | - | $1.5B | 187.5x | ||
| Private | - | - | $650M | - | ||
| Publicly listed | $94B | $40B | $651B | 6.8x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x | ||
| Publicly listed | $25B | $6.9B | $149B | 6.6x | ||
| Publicly listed | $6.9B | $1.8B | $44B | 6.2x |
Biolinq Public Comps
Biolinq is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Biolinq competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Biolinq
| When was Biolinq founded? | Biolinq was founded in 2012. |
| Where is Biolinq headquartered? | Biolinq is headquartered in San Diego, CA, United States. |
| Is Biolinq publicly listed? | No, Biolinq is a private, VC-backed company. |
| How much funding has Biolinq raised? | Biolinq has raised $273M across 5 funding rounds. |
| What was Biolinq's last funding round? | Biolinq's last funding round was a $100M Series C in March 2025, led by Alpha Wave Ventures. |
| Who are Biolinq's investors? | Biolinq's investors include M Ventures, LifeSci Venture Partners, Hikma Ventures, RiverVest, Aphelion Capital, Features Capital, Alpha Wave Ventures, Taisho Pharmaceutical Holdings, JDRF T1D Fund, AXA Alternative Investments and 7 others. |
| Which companies are comparable to Biolinq? | Companies comparable to Biolinq include MindMaze, Galvanize Therapeutics, Johnson & Johnson, Thermo Fisher Scientific, Danaher and Agilent. |
See companies similar to Biolinq
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




